A natural supplement and exercise for ongoing inflammation in people with long COVID
Tests a natural supplement, with and without exercise, in adults with long COVID.
Plain-language title generated from the registry record
Registry title: Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection
Key facts
- Where
- Murcia, SpainSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07397910, who can take part
Where in Spain
- UCAM HiTech, Sport & Health Innovation HubMurcia, SpainNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universidad Católica San Antonio de Murcia
- Trial code
- NCT07397910
- Record updated
- 9 February 2026
- Original description
A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chronic symptoms and, consequently, their quality of life.Read full original descriptionShow less
Clinical Trial to Analyze the Effectiveness of a Natural Compound on Chronic Immune-mediated Inflammatory Status in Subjects Who Have Had SARS-CoV-2 Infection.
A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chronic symptoms and, consequently, their quality of life.
Inclusion: Subjects of both sexes; Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA; Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness; No history of sequelae from a severe acute illness.
Exclusion: Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment; Subjects with an underlying disease that explains the clinical manifestations; Presence of chronic inflammatory diseases; Subjects with acute infections; Hypersensitivity or intolerance to any of the components of the study products; Severe or terminal illnesses; Excessive alcohol consumption; Use of any nutraceutical or dietary supplement; Subjects with a body mass index (BMI) over 32; Pregnant or lactating women.